oxybutynin Tablets 2.5 mg, 5 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
Canada
GMP approvals
Canada
Comments
Reference product : Ditropan XL (Janssen)
Manufacturer #278
The company has become a prominent partner of the pharmacy community in North America, with the fastest rising market share among generic leaders. It can provide best-in-class supply reliability thanks to production capacity. In more than 50 countries, it's available locally or through corporate partnerships. R&D expenditures range from $40 million to $50 million per year. They are dedicated to maintaining a customer satisfaction rate of over 95% by continuously enhancing supply chain efficiency.
Oxybutynin is a medication used to treat overactive bladder. Suppliers market it as oxybutynin oral tablets, transdermal patches, topical gels and it is available as immediate and delayed-release formulations.
The drug was first approved for medical use in 1975, and by now has reached widespread use, with over 6 million prescriptions registered yearly in the U.S. alone. Multiple manufacturing companies and drug vendors populate the global oxybutynin market, including major suppliers such as Sanofi-Aventis, Mylan, Accord Healthcare, and many others.
Suppliers market both generic and trade name oxybutynin medications. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail prices per 60 (5mg) tablets of oxybutynin fall into an approximate range of 7.50 EUR to 10.00 EUR.